{"component": "definition", "props": {"groups": [{"snippet": "means an additional indication of the medicinal product which was approved by SIDC after the original registration of the medicinal product.", "snippet_links": [{"key": "additional-indication", "type": "definition", "offset": [9, 30]}, {"key": "medicinal-product", "type": "clause", "offset": [38, 55]}, {"key": "approved-by", "type": "definition", "offset": [66, 77]}, {"key": "registration-of-the", "type": "clause", "offset": [102, 121]}], "size": 11, "samples": [{"hash": "9bmnEAkKcKn", "uri": "https://www.aifp.sk/upload/files/Etika/AIFP%20Ethical%20Code%2001.07.2024.pdf", "label": "www.aifp.sk", "score": 17.5741538911, "published": false}, {"hash": "91ipeTbd9Vj", "uri": "https://aifp.sk/upload/files/Etika/EC%20AIFP_02012024%20(2).pdf", "label": "aifp.sk", "score": 10.0116358658, "published": false}, {"hash": "iyoEL8zmutI", "uri": "https://www.aifp.sk/upload/files/Etika/EC%20AIFP_23082022.pdf", "label": "www.aifp.sk", "score": 9.3230663929, "published": false}], "hash": "1e662352a59224f8f6d6b003979e90b3", "id": 1}, {"snippet": "means any indication for the Product other than the Initial Indications, which is subject to Takeda\u2019s right of first refusal as provided in Section 3.2.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [25, 36]}, {"key": "initial-indications", "type": "definition", "offset": [52, 71]}, {"key": "subject-to", "type": "definition", "offset": [82, 92]}, {"key": "right-of-first-refusal", "type": "clause", "offset": [102, 124]}, {"key": "section-32", "type": "clause", "offset": [140, 151]}], "size": 3, "samples": [{"hash": "fy1KL448wUe", "uri": "/contracts/fy1KL448wUe#new-indications", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "fbffL2QHwh5", "uri": "/contracts/fbffL2QHwh5#new-indications", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "hash": "2254ab41e321449c9170cb5b80a97c7b", "id": 2}, {"snippet": "means any indication outside the Field (excluding Autoimmune Indications, Stem Cell Transplantation and Transplantation Indications).", "snippet_links": [{"key": "outside-the-field", "type": "definition", "offset": [21, 38]}, {"key": "autoimmune-indications", "type": "definition", "offset": [50, 72]}, {"key": "stem-cell", "type": "definition", "offset": [74, 83]}], "size": 2, "samples": [{"hash": "6NN2v5WNSsY", "uri": "/contracts/6NN2v5WNSsY#new-indications", "label": "Development and License Agreement (Biocryst Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "dhWfIF4qMhv", "uri": "https://ir.biocryst.com/static-files/837f2a1b-cad0-427c-bb22-d14444c1f5db", "label": "ir.biocryst.com", "score": 8.9650924025, "published": false}], "hash": "88c70225b3b2eabbf0d60561e21dbc15", "id": 3}, {"snippet": "has the meaning set forth in Section 4.02(c).", "snippet_links": [], "size": 2, "samples": [{"hash": "8UBVuPrLSDb", "uri": "/contracts/8UBVuPrLSDb#new-indications", "label": "Asset Purchase Agreement (Horizon Therapeutics Public LTD Co)", "score": 32.1485284052, "published": true}, {"hash": "awYluC6wkTh", "uri": "/contracts/awYluC6wkTh#new-indications", "label": "Asset Purchase Agreement (Hyperion Therapeutics Inc)", "score": 23.392881588, "published": true}], "hash": "f5f962e7aeb91968a5cab6c1492f6d28", "id": 4}, {"snippet": "means clinical indications, uses and applications for the Product other than what is included in the Field.", "snippet_links": [{"key": "applications-for", "type": "clause", "offset": [37, 53]}, {"key": "the-product", "type": "clause", "offset": [54, 65]}, {"key": "in-the-field", "type": "clause", "offset": [94, 106]}], "size": 2, "samples": [{"hash": "jBpeobWZlOr", "uri": "/contracts/jBpeobWZlOr#new-indications", "label": "License and Distribution Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "aGDwyZRwi0I", "uri": "/contracts/aGDwyZRwi0I#new-indications", "label": "License and Distribution Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "451ee0e01fcef893da9bee3207793258", "id": 5}, {"snippet": "means any indication identified by KSB in which the Product may be used in addition to the Indications (including metastatic brain cancers ).", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [48, 59]}, {"key": "in-addition-to-the", "type": "clause", "offset": [72, 90]}], "size": 1, "samples": [{"hash": "3DcmxRCO497", "uri": "/contracts/3DcmxRCO497#new-indications", "label": "Licensing and Supply Agreement (Xenova Group PLC)", "score": 20.0, "published": true}], "hash": "94ddea3405fbdd671dcf1d8142d1b9e8", "id": 6}, {"snippet": "means any indication for the Product other than the Initial Indications, which is subject to Takeda\u2019s right of first refusal as provided in Section 3.2. \u201cParty\u201d or \u201cParties\u201d shall have the meaning set forth in the introductory paragraph. \u201cPhase IV Studies\u201d shall mean clinical studies performed after obtaining Marketing Authorization for the purpose of supporting the marketing and Commercialization of the Product. For the avoidance of any doubt, \u201cPhase IV Studies\u201d does not include the RRS (as hereinafter defined). \u201cPost-Marketing Surveillance\u201d shall mean all post-marketing safety surveillance in the Initial Territory with respect to the Product that is required by a Regulatory Authority in the Initial Territory or any Additional Territory in which the Products are being Developed or Commercialized. \u201cPrimary Detail Equivalent\u201d or \u201cPDE\u201d shall mean (a) one Primary Product Detail or (b) [**] Secondary Product Details.", "snippet_links": [{"key": "initial-indications", "type": "definition", "offset": [52, 71]}, {"key": "subject-to", "type": "definition", "offset": [82, 92]}, {"key": "right-of-first-refusal", "type": "clause", "offset": [102, 124]}, {"key": "section-32", "type": "clause", "offset": [140, 151]}, {"key": "introductory-paragraph", "type": "definition", "offset": [214, 236]}, {"key": "phase-iv-studies", "type": "definition", "offset": [239, 255]}, {"key": "clinical-studies", "type": "clause", "offset": [268, 284]}, {"key": "marketing-authorization", "type": "clause", "offset": [311, 334]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [335, 353]}, {"key": "commercialization-of-the-product", "type": "clause", "offset": [383, 415]}, {"key": "initial-territory", "type": "definition", "offset": [606, 623]}, {"key": "with-respect-to", "type": "clause", "offset": [624, 639]}, {"key": "required-by", "type": "definition", "offset": [660, 671]}, {"key": "regulatory-authority", "type": "definition", "offset": [674, 694]}, {"key": "additional-territory", "type": "definition", "offset": [727, 747]}, {"key": "the-products", "type": "clause", "offset": [757, 769]}, {"key": "primary-detail-equivalent", "type": "definition", "offset": [810, 835]}, {"key": "primary-product", "type": "definition", "offset": [865, 880]}, {"key": "product-details", "type": "clause", "offset": [910, 925]}], "size": 1, "samples": [{"hash": "a9lub0q6F8l", "uri": "/contracts/a9lub0q6F8l#new-indications", "label": "Collaboration and License Agreement", "score": 31.340862423, "published": true}], "hash": "d89e397867b3575cf0f904db2f084375", "id": 7}, {"snippet": "means IPF, TB, FI and any additional new indications in human beings that may be mutually agreed by the Parties after the Effective Date.", "snippet_links": [{"key": "by-the-parties", "type": "clause", "offset": [97, 111]}, {"key": "after-the-effective-date", "type": "clause", "offset": [112, 136]}], "size": 1, "samples": [{"hash": "6G89tD0cCCf", "uri": "/contracts/6G89tD0cCCf#new-indications", "label": "Development and Marketing Agreement (Intermune Pharmaceuticals Inc)", "score": 19.0, "published": true}], "hash": "55ae3cf8b80bc46447bdb24b40e34d50", "id": 8}, {"snippet": "means any indication of a disease state other than the Indications, that is developed as part of the Joint Development Program (excluding diagnosis).", "snippet_links": [{"key": "disease-state", "type": "definition", "offset": [26, 39]}, {"key": "joint-development-program", "type": "clause", "offset": [101, 126]}], "size": 1, "samples": [{"hash": "bbJjCC4GzF", "uri": "/contracts/bbJjCC4GzF#new-indications", "label": "License and Development Agreement (Insmed Inc)", "score": 18.0, "published": true}], "hash": "ee373c8a08ab9b558a522f34724e893b", "id": 9}, {"snippet": "means, with respect to any Product, any Indication (other than the Initial Indications) approved by the JSC pursuant to Sections \u200e3.1(a) and \u200e3.4 in which such Product may be Developed, Manufactured and Commercialized under this Agreement.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "initial-indications", "type": "definition", "offset": [67, 86]}, {"key": "approved-by", "type": "definition", "offset": [88, 99]}, {"key": "pursuant-to-sections", "type": "clause", "offset": [108, 128]}, {"key": "this-agreement", "type": "clause", "offset": [224, 238]}], "size": 1, "samples": [{"hash": "2k7mafEnCnF", "uri": "/contracts/2k7mafEnCnF#new-indications", "label": "License Agreement (Y-mAbs Therapeutics, Inc.)", "score": 31.9733059548, "published": true}], "hash": "029ef80cb46a0337d5649e1241bc34aa", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYbmV3LWluZGljYXRpb25zIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "means an additional indication of the medicinal product which was approved by SIDC after the original registration of the medicinal product.", "size": 28, "title": "New indication(s)", "id": "new-indications", "examples": [], "related": [["collaboration-product", "Collaboration Product", "Collaboration Product"], ["new-product", "New Product", "New Product"], ["us-territory", "U.S. Territory", "U.S. Territory"], ["licensed-territory", "Licensed Territory", "Licensed Territory"], ["second-indication", "Second Indication", "Second Indication"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}